Auriga
Auriga USA is a research and trading platform that focuses on growth sectors within the Health Care and Technology verticals. We operate out of our main office in New York City, and also have satellite offices in Boston, San Francisco, Philadelphia, San Diego, and Washington D.C. This regional network helps us to keep abreast of key corporate developments, enhance client relationships, and provide more efficient product distribution to meet clients' investment needs. The firm is committed to providing our clients with critical information flow, investment ideas, and access to industry experts.
View Older Stories
-
Form X-17A-5 AURIGA USA, LLC For: Dec 31
-
Sangamo Therapeutics, Inc. Announces Acquisition of TxCell
-
Sangamo Therapeutics to Acquire TxCell
-
Sangamo Therapeutics to Acquire TxCell
-
SDLP - Seadrill Partners LLC Announces First Quarter 2018 Results
-
Vectalys and FlashCell Announce Merger to Create Flash Therapeutics, New Gene Therapy Company Based on Lentiviral Platforms and Bioproduction Technologies
-
Auriga (UTSI) PT Raised to $6 at Northland Capital Markets
-
JDA Announces 2018 Real Results Award Winners
-
TxCell Announces That All Management Resolutions Supported by the Board of Directors Were Approved with More Than 94% During Its Annual Meeting of Shareholders
-
Form X-17A-5 AURIGA USA, LLC For: Dec 31
-
U.S. Polyester Producers Applaud U.S. International Trade Commission's Affirmative Final Determination on Imports of Fine Denier Polyester Staple Fiber from China and India
-
U.S. Polyester Producers Applaud U.S. Department of Commerce's Affirmative Final Countervailing Duty Determinations on Imports of Fine Denier Polyester Staple Fiber from China and India
-
U.S. Polyester Producers Applaud Overall Affirmative Preliminary Antidumping Duty Determinations Announced by the U.S. Department of Commerce on Imports of Fine Denier Polyester Staple Fiber from Chin
-
UTStarcom Holdings (UTSI) PT Raised to $5 at Northland Capital Markets
-
Computer Programs & Systems (CPSI) Appoints Regina Benjamin, Denise Warren & Glenn Tobin to Board
-
CPSI Adds Three Experienced Directors to Board
-
ERYTECH Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
-
U.S. Polyester Producers Applaud U.S. Department of Commerce's Affirmative Preliminary Countervailing Duty Determinations on Imports of Fine Denier Polyester Staple Fiber from China and India
-
aveni(R) S.A. Raises EUR 8.9M ($10.5M) in Series B Financing from Merck Ventures and Existing Investors to Commercialize its Innovative Metallization Technologies
-
Trevor Kidd Joins Brock Capital Group as a Senior Managing Director
-
Trevor Kidd Joins Brock Capital Group as a Senior Managing Director
-
Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
-
Gamida Cell Announces $3.5 Million Grant from the Israeli Government
-
U.S. Polyester Producers Applaud U.S. International Trade Commission's Affirmative Preliminary Determination on Imports of Fine Denier Polyester Staple Fiber from China, India, Korea, and Taiwan
-
Mizuho Expands Healthcare Equity Research with SMID Cap Biotechnology Hire
-
Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
-
Gamida Cell Announces $40 Million Private Financing
-
Gamida Cell Appoints Nobel Prize Laureate Professor Roger Kornberg and Immune Oncology Expert Dr. Michael Perry to its Board of Directors
-
U.S. Producers of Fine Denier Polyester Staple Fiber File Trade Petitions Against Five Countries
-
Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation
-
Glory’s TellerInfinity™ Assisted Service Solution Achieves Certification with Auriga’s WWS Software
-
PET Resin Producers, Packaging Companies, Brand Owners Heading to Medellin, Colombia for CMT's 5th SCAPET, this June
-
Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord® in Haematopoietic Stem Cell Transplantation (HSCT)
-
Form X-17A-5/A AURIGA USA, LLC For: Dec 31
-
Form X-17A-5 AURIGA USA, LLC For: Dec 31
-
Form X-17A-5 AURIGA USA, LLC For: Dec 31
-
Gamida Cell Announces First Patient Transplanted in Phase 3 Registration Study of NiCord for Blood Cancers
-
SDLP - Seadrill Partners LLC Announces Fourth Quarter 2016 Results
-
WiLAN Subsidiary Acquires Patent Portfolio from GLOBALFOUNDRIES
-
Gamida Cell Presents Positive Data From Phase 1/2 Study of NiCord® as a Curative Treatment for Sickle Cell Disease at ASH 2016
-
Capella Hotel Group Asia and Pierre Gagnaire Make Joint Debut In Mainland China with "Comptoir Pierre Gagnaire" at Capella Shanghai, Jian Ye Li
-
Gamida Cell Names Julian Adams, Ph.D. New Chairman of the Board
-
Capella Hotel Group Continues Asian Expansion With Luxury Tented Retreat: Capella Ubud, Bali
-
Gamida Cell Receives FDA Breakthrough Therapy Designation For NiCord®
-
MyTeller Solution - A Step by Step Approach to Branch Transformation
-
Gamida Cell Announces Appointment of Julian Adams, Ph.D. and Kenneth I. Moch to its Board of Directors
-
Arno Completes $2.8 Million Private Placement
-
Gamida Cell Announces First Patient with Sickle Cell Disease Transplanted in Phase 1/2 Study of CordIn™ as the Sole Graft Source
-
H1 2016 Sales: +7% to EUR 8.9m
-
SuperSonic Imagine: H1 2016 Sales: +7% to €8.9m
